Promising mouse studies and billions of dollars in funding are stoking excitement. But we’ve been here before.

The approach relies on “reprogramming” cells to a younger state. It’s one of many strategies being explored by biotech ...

Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...

Test time has arrived: the first person has been treated in a highly anticipated gene therapy trial that aims to coax aged ...

Reversing cellular age isn’t science fiction, but the biology is more complicated than either the skeptics or the hype ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biotech startup NewLimit secures a major funding round after claiming a ‘breakthrough discovery’ of a prototype medicine that ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the "recipe" for the transformation. Researchers at Lund University have now created ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Reprogram Biosciences, a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, today announced the close of its seed financing. The close brings total ...

The world's first reverse aging drug, ER-100, was injected into a human on June 9, 2026 The post The World’s First ...